personalized medicine in inflammation network
the specific objectives of this funding opportunity are:
- to develop clinically applicable personalized pharmacotherapy approaches to medicine for immune mediated inflammatory musculoskeletal diseases
- to develop novel approaches to patient identification, classification, and stratification in immune mediated inflammatory musculoskeletal disorders
- to accelerate the translation of basic research discoveries into daily clinical practice
- to evaluate outcomes of interventions based on novel personalized medicine paradigms to demonstrate impact
- to generate country specific economic analyses based on novel personalized medicine approaches
to achieve the objectives and to add value to the research enterprise, the network will:
- possess world-class capacity to address the identified research problem(s), challenge(s), or opportunity(ies)
- build a critical mass of technical and scientific expertise on a national and international scale to provide research leadership and enhance impact by bringing together a unified group of investigators and other stakeholders
- identify key knowledge gaps and promote/create national and international collaborations among researchers from multiple research pillars (i.e., biomedical, clinical, health systems and services, population and public health) and with knowledge users to address those gaps in a coherent fashion
- integrate research and knowledge translation projects into a coherent program which will generate solutions that will be implemented to produce social and economic benefits for both countries
- promote and facilitate the sharing of ideas, tools, methods, and resources and the dissemination of research outcomes
- incorporate a training and career development component
relevant research areas
the network must strive to harness the potential from multiple population-based patient cohorts and registries; and use state of the art platforms and technologies in order to develop personalized medicine approaches for immune mediated inflammatory musculoskeletal diseases.